Financial Performance - Revenue for Q3 2024 was CNY 106,155,066.27, a decrease of 7.15% compared to the same period last year[1] - Net profit attributable to shareholders was CNY -2,063,082.26, representing a decline of 102.99% year-on-year[1] - Net profit excluding non-recurring items was CNY -3,290,961.45, down 70.35% from the previous year[1] - Cash flow from operating activities was CNY -25,080,901.14, a decrease of 122.47% compared to the same period last year[1] - Total operating revenue for Q3 2024 reached CNY 354,472,693.30, an increase of 5.9% compared to CNY 335,143,687.81 in the same period last year[21] - Net profit for the period was CNY -962,035.15, a significant decrease from CNY 48,452,894.63 in the previous year, indicating a shift to a loss[22] - The total comprehensive income attributable to the parent company was 8,089,554.12 yuan, compared to 61,365,294.29 yuan in the previous period, indicating a significant decline[23] - The company reported a basic and diluted earnings per share of 0.0037 yuan, compared to 0.0281 yuan in the previous period[23] Assets and Liabilities - Total assets as of September 30, 2024, were CNY 5,299,799,872.06, down 1.47% from the end of the previous year[1] - The total assets as of the end of Q3 2024 were CNY 5,299,799,872.06, compared to CNY 5,378,612,557.62 at the end of the previous quarter[20] - Total liabilities increased to CNY 139,599,759.03 from CNY 137,145,270.06, reflecting a rise of 1.8%[20] - The company's total equity decreased to CNY 5,160,200,113.03 from CNY 5,241,467,287.56, indicating a decline of 1.6%[20] Cash Flow - The net cash flow from operating activities was -25,080,901.14 yuan, a decrease from 111,632,734.66 yuan in the same period last year[25] - Cash inflow from operating activities totaled 372,845,207.31 yuan, down from 494,681,426.00 yuan year-over-year[24] - The net cash flow from investing activities was -110,143,377.46 yuan, a decrease from 249,470,398.54 yuan in the previous year[25] - Cash and cash equivalents at the end of the period amounted to 2,531,158,919.42 yuan, down from 2,784,473,389.92 yuan at the end of the previous period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 51,038[6] - The largest shareholder, Shanghai Yueye Equity Investment Management Partnership, holds 19.13% of shares, totaling 414,138,066 shares[6] - The second-largest shareholder, Xinjiang Kaidi Investment Co., Ltd., holds 18.93% of shares, totaling 409,748,445 shares, with 193,000,000 shares pledged[6] - The third-largest shareholder, Merrill Holdings Group, holds 13.57% of shares, totaling 293,730,162 shares, which are frozen[6] - The top ten shareholders account for a significant portion of the total share capital, with the largest three shareholders alone holding over 51%[11] Share Repurchase and Future Plans - The company expects a net profit attributable to shareholders of 8 million to 12 million RMB for the first half of 2024, with a net profit of 6.5 million to 9.5 million RMB after deducting non-recurring gains and losses[14] - The company plans to repurchase shares with an amount not less than 200 million RMB and not exceeding 300 million RMB[14] - The company has a total of 24,176,500 shares held in the repurchase special securities account, accounting for 1.12% of the total share capital[13] - The company plans to repurchase shares at a price not exceeding RMB 3.59 per share, with a total repurchase amount between RMB 200 million and RMB 300 million[16] - As of September 10, 2024, the company has repurchased a total of 21,649,500 shares, accounting for 1.00% of the total share capital, with a total transaction amount of RMB 53,814,234[16] Impairment and Other Financial Issues - The company has recognized an asset impairment provision of RMB 10.44 million for the first half of 2024 due to indications of impairment in accounts receivable and inventory[16] - The company is involved in litigation due to contractual disputes with former controlling shareholder Meilin Holdings Group Co., Ltd., and other related parties[17] - The company has not yet received the performance compensation from Meilin Holdings as per the performance commitment agreement, leading to arbitration proceedings initiated by Kaidi Investment[16] Operational Metrics - The company experienced a decrease in sales revenue from 468,449,864.07 yuan to 346,545,223.78 yuan year-over-year[24] - Total operating costs amounted to CNY 333,494,551.73, up from CNY 328,972,818.54, reflecting a year-over-year increase of 1.6%[21] - Research and development expenses for Q3 2024 were CNY 36,148,711.02, slightly down from CNY 37,686,122.01 in the prior year[22] - The company reported a decrease in sales expenses to CNY 61,587,510.18 from CNY 65,687,800.69, a reduction of 6.4%[21] Other Financial Information - The company has reported a change in shareholding due to judicial enforcement, with Merrill Holdings having 21,649,438 shares executed, resulting in a change of over 1% in their holdings[14] - The company has not disclosed any other significant shareholder relationships or actions beyond those mentioned[11] - The company's inventory as of September 30, 2024, was RMB 210,732,288.05, slightly up from RMB 207,560,244.65 at the beginning of the period[18] - The company's other receivables slightly increased to RMB 323,887,686.97 from RMB 322,201,651.98 at the beginning of the period[18] - Deferred income tax assets increased to CNY 22,282,509.32 from CNY 15,046,330.90, showing a growth of 48.3%[19] - The company's cash and cash equivalents as of September 30, 2024, amounted to RMB 2,628,102,317.69, a decrease from RMB 2,796,417,277.38 at the beginning of the period[18] - The report for the third quarter was not audited[26]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、德展大健康股份有限公司（以下简称"公司"）本次续聘会计师事务所 事项符合财政部、国务院国资委、中国证监会印发的《国有企业、上市公司选聘 会计师事务所管理办法》（财会〔2023〕4 号）的规定。 公司于 2024 年 10 月 29 日召开公司第八届董事会第二十九次会议，会议审 议通过了《关于续聘会计师事务所的议案》，拟续聘中兴财光华会计师事务所（特 殊普通合伙）（以下简称"中兴财光华会计师事务所"）为公司 2024 年度财务 报告和内部控制审计机构，现将相关事项公告如下： 一、拟续聘会计师事务所事项的情况说明 中兴财光华会计师事务所是中国会计师事务所行业中机构健全、制度完善、 规模较大、发展较快、综合实力较强的专业会计服务机构，其具有财政部、中国 证监会核准的证券、期货相关业务资格，具备多年为上市公司提供优质审计服务 的丰富经验和强大的专业服务能力，能够较好地满足公司建立健全内部控制以及 财务审计工作的要求。 证券代码：000813 证券简称：德展健康 公告编号：2024-053 德展大健康股份有 ...

德展大健康股份有限公司 关于召开 2024 年第二次临时股东大会的通知 证券代码：000813 证券简称：德展健康 公告编号：2024-054 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据德展大健康股份有限公司（以下简称"公司"、"德展健康"）第八届 董事会第二十九次会议审议通过的有关议案，公司定于 2024 年 11 月 19 日召开 2024 年第二次临时股东大会。现将有关事项通知如下： 一、召开会议基本情况 1、股东大会届次：2024 年第二次临时股东大会 2、召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《证券 法》《深圳证券交易所股票上市规则》和《公司章程》等有关规定。 4、会议召开的日期、时间： 现场会议召开时间为 2024 年 11 月 19 日下午 14:30 分 网络投票时间为 2024 年 11 月 19 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 11 月 19 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通过深圳证券交易所互 联网投票 ...

德展大健康股份有限公司 第八届监事会第十八次会议决议公告 证券代码：000813 证券简称：德展健康 公告编号：2024-051 该议案审议获得通过。 具体内容详见公司同日在《证券时报》《上海证券报》《中国证券报》《证 券日报》、巨潮资讯网（http://www.cninfo.com.cn）披露的《2024 年第三季度 报告》（公告编号：2024-052）。 三、备查文件 1 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 德展大健康股份有限公司（以下简称"公司"）第八届监事会第十八次会议 的通知已于 2024 年 10 月 26 日以电子邮件方式发出；公司于 2024 年 10 月 29 日 10:30 以通讯表决方式召开。本次会议应参加会议监事 4 人，实际参加会议监事 4 人。会议由监事会主席杨延超先生主持。本次会议的召集、召开符合《公司法》 及《公司章程》规定。 二、监事会会议审议情况 （一）关于公司 2024 年第三季度报告的议案 公司依据 2024 年第三季度生产经营情况编制了《德展大健康股份有限公司 2024 年第三季度报 ...

证券代码：000813 证券简称：德展健康 公告编号：2024-049 德展大健康股份有限公司 一、本次诉讼进展暨冻结事项概述 根据美林控股与广州融晟间的合同纠纷及广州融晟的申请，广州中院下达 （2024）粤 01 民初 476 号《民事裁定书》，裁定冻结美林控股、德展金投集团 有限公司、张湧、美林资源有限公司、中呈资本(深圳)有限公司、银帝集团有限 公司、汪宾、德展健康及美林谷文化旅游产业有限公司名下价值人民币 547,911,111.11 元的银行存款或查封、扣押其他等值财产。有关上述事项具体内 容详见公司于 2024 年 8 月 31 日在巨潮资讯网（www.cninfo.com.cn）等指定信 息披露媒体发布的《关于公司诉讼事项的公告》（公告编号：2024-043）。 近日，公司通过公开渠道查询获悉，公司所持部分子公司及参股公司股权因 上述（2024）粤 01 民初 476 号《民事裁定书》的执行，被广州中院依法冻结。 冻结涉及公司控股子公司汉萃（天津）生物技术股份有限公司（以下简称"汉萃 天津"）、德佳康（北京）生物科技有限公司（以下简称"德佳康"），以及公 司参股公司北京东方略生物医药科技股份有限 ...

证券代码：000813 证券简称：德展健康 公告编号：2024-048 德展大健康股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036）。 根 ...

证券代码：000813 证券简称：德展健康 公告编号：2024-047 德展大健康股份有限公司 关于公司持股 5%以上股东所持部分公司股份 被司法拍卖的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、美林控股集团有限公司（以下简称"美林控股"）持有德展大健康股份 有限公司（以下简称"公司"）293,730,162 股股份，占公司总股本的比例为 13.57%。 本次将被司法拍卖的股份为美林控股持有的 64,948,680 股公司股份（股份性质 为无限售流通股），占公司股份总数的 3.00%，美林控股所持公司股份均已被司 法冻结。 2、截至本公告披露日，本次拍卖事项尚在公示阶段，根据相关规定，法院 有权在拍卖开始前、拍卖过程中中止拍卖或撤回拍卖，后续可能涉及竞拍、缴款、 股权变更过户等环节，拍卖结果存在不确定性。 公司于近日通过网络查询获悉，公司持股 5%以上股东美林控股所持公司 64,948,680 股股份被北京市第三中级人民法院定于 2024 年 10 月 30 日 10 时至 2024 年 10 月 31 日 10 时止（延时的除 ...

Company Overview - Dezheng Health focuses on drug research, production, and sales, with involvement in peptide applications, industrial hemp, and health management [1] - Core subsidiary, Jialin Pharmaceutical, established in 1998, recognized as a high-tech enterprise and ranked among the top 50 in China's pharmaceutical industry in 2016 [1] - Jialin has 3 production bases and 1 testing center, all certified by the latest GMP standards [1][2] Shareholding Structure - The controlling shareholder is the Xinjiang State-owned Assets Supervision and Administration Commission, holding 24.79% of shares through Xinjiang Jintou and its subsidiaries [2] - Dezheng Health is the only state-controlled biopharmaceutical listed company under Xinjiang Jintou [2] Financial Status - As of June 2024, total assets are CNY 5.365 billion, with net assets of CNY 5.228 billion and a debt-to-asset ratio of 2.55% [2] - Cash assets amount to CNY 2.775 billion, representing 51.72% of total assets [2] Business Segments Pharmaceutical Segment - Product portfolio includes chemical drugs, biological drugs, and DNA drugs [2] - Key products: "A Le" and "Ni Le" for cardiovascular treatment; innovative drugs in development include WYY (neuroprotective agent) and ZT (antithrombotic) [2][3] Health Management Segment - Projects include a comprehensive health management complex in Hainan and a psychiatric rehabilitation hospital in Wuhan with over 300 planned beds [2][3] Aesthetic Medicine - Focus on recombinant collagen products and wound dressings [3] Development Strategy - Emphasis on stabilizing core business and expanding product lines through mergers and acquisitions [3][5] - Plans to accelerate the development of key innovative drugs and enhance market competitiveness [3][5] R&D and Innovation - R&D team consists of nearly 200 personnel, with R&D investment accounting for approximately 10% of revenue [2] - WYY project aims to develop a multi-target neuroprotective agent, with promising preclinical results [4] - VGX-3100, a DNA therapy for HPV-related cervical lesions, is in phase III clinical trials, with significant potential for market impact [4] Market Performance and Future Outlook - Core products maintain a gross margin of approximately 55-60% despite recent declines due to centralized procurement [3] - Positive growth in revenue and net profit reported in the mid-2024 financial results [3] - Ongoing efforts to enhance market presence and shareholder value through strategic initiatives and stock repurchase programs [5]

证券代码：000813 证券简称：德展健康 公告编号：2024-046 德展大健康股份有限公司 关于参股公司合作研发项目新适应症 获得临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）于近日收到公司参股公司北 京东方略生物医药科技股份有限公司（以下简称"东方略"）的通知，东方略于 近日收到国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》 （编号 2024LP02122），批准了其与美国 Inovio Pharmaceuticals, Inc.（以下简称 "Inovio 公司"）合作研发的 VGX-3100 项目针对 HPV-16/18 相关肛门癌前病变 的 II 期临床试验申请。现将有关情况公告如下： 一、VGX-3100 临床试验申请相关情况 VGX-3100 是东方略与 Inovio 公司在 DNA 免疫治疗领域的重点合作开发项 目，用于治疗由人类乳头状瘤病毒（HPV）导致的癌前病变，东方略拥有产品在 大中华区（中国大陆、香港、澳门、台湾）开发、生产和商业化的独家权利。此 前 V ...

Group 1: Core Products and Market Position - The company's main products, "Alo" (Atorvastatin Calcium Tablets) and "Nile" (Amlodipine Atorvastatin Calcium Tablets), account for over 90% of total revenue [1] - "Alo" is the first domestic generic version of the original drug Lipitor, with a stable price after multiple rounds of centralized procurement [1] - The demand for lipid-lowering medications is increasing, particularly among younger populations, indicating a potential market growth trend [1] Group 2: Product Development and Pipeline - The company is focusing on the development of existing products and new projects, including the innovative drug WYY for acute ischemic stroke, which has shown promising results in animal studies [3] - The company plans to accelerate the commercialization of semaglutide, a GLP-1 receptor agonist for diabetes and obesity, with a projected global sales figure of approximately $21.6 billion for 2023 [3] - The recombinant human collagen project is in progress, with plans for market entry in both cosmetic and pharmaceutical applications [4] Group 3: Strategic Initiatives and Financial Health - The company has a robust cash reserve and plans to pursue acquisitions to enhance its product pipeline and market presence [5] - The total investment for the Hainan Dezheng International Health and Wellness Complex project is approximately 489.36 million yuan, with a total construction area of about 71,828 square meters [5] - The company is actively managing its market value and is committed to stock repurchase as part of its value enhancement strategy [6]